Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage

Sky Labs showcased its ring-type cuffless blood pressure monitor, CART BP pro, at the Digital Biomarkers in Clinical Trials Summit to position the platform as a partner for high-quality vital-sign data in drug trials and Real-World Evidence (RWE). The company highlighted that conventional cuff-type ABPM disrupts sleep—citing a 2011 study where 70.2% of users reported sleep disruption and failure to collect adequate 24-hour data rose to 50.0% among low-tolerability participants—while CART BP pro is designed to avoid repeated arm constriction. CART BP pro already has South Korean national health insurance coverage and is officially recommended in revised Korean hypertension guidelines, supporting broader adoption for clinical research and therapeutic response monitoring.

Analysis

This is more meaningful as a procurement signal than a near-term revenue event. If pharma accepts cuffless vitals as a trial-grade data source, the economic winners are the platforms that can reduce subject dropout, shorten enrollment-to-readout cycles, and lower site monitoring costs; that favors niche data-collection vendors and trial-enablement software more than the large drugmakers in attendance. For NVS and RHHBY, the first-order impact is negligible, but over 12-24 months they could be among the buyers that accelerate standardization if the workflow integrates cleanly into multicenter protocols.

The less obvious loser is the incumbent ambulatory BP device ecosystem: traditional cuff-based monitoring tools may not disappear, but their pricing power weakens if sponsors increasingly specify continuous, lower-burden wearables in protocol design. The second-order effect is on CROs and sites, where better adherence could improve data completeness and reduce repeat measures, compressing trial operating expense. That said, the market should treat this as optionality until there are named pharma pilot programs or a protocol amendment from a regulated sponsor.

The main risk is execution, not technology theater: without reproducible data integrity, validated interoperability, and privacy/security controls, adoption stays confined to pilot studies and domestic reimbursements. In the next 1-3 months, the catalyst is partnership announcements; over 6-18 months, it is whether one or two global pharma programs move from exploratory use to standard endpoint collection. If that does not happen, the current optimism likely fades into another conference-driven wearable story.

Key Decisions for Investors

• No immediate equity trade in NVS or RHHBY; treat this as a customer-technology watch item rather than a revenue catalyst. Reassess only if either name publicly references trial-design changes or vendor adoption in upcoming pipeline updates.
• Set an alert on WLDS and other ring-wearable names for trial-partnership announcements over the next 1-3 months; buy only on evidence of commercial contracts, not conference visibility. Until then, upside is narrative-driven and likely fades.
• Short the weaker incumbent ABPM ecosystem on any rally if a listed proxy emerges; the thesis is not device obsolescence but gradual share loss to lower-friction monitoring in clinical protocols. Falsify if sponsor adoption stalls or if cuffless data fails validation in multi-site studies.
• Watch for a CRO read-through rather than a pharma read-through: if trial vendors begin citing lower dropout or faster data lock, that is the cleaner tradeable signal. The first durable beneficiary would be operationally exposed trial services, not the drugmakers themselves.